President Donald Trump makes an announcement from the Oval Workplace on the White Home in Washington, Nov. 6, 2025.
Jonathan Ernst | Reuters
President Donald Trump on Thursday introduced the launch of TrumpRx — a direct-to-consumer web site that’s key to his administration’s efforts to decrease prescription drug prices within the U.S.
The president mentioned hundreds of thousands of Individuals would get monetary savings by way of the platform. However it’s nonetheless unclear if all sufferers — notably these with insurance coverage protection — will see extra price financial savings from utilizing that web site to purchase their medicines than they might by way of present strategies. TrumpRx targets people who find themselves prepared to pay with money and forgo insurance coverage, which means that sufferers with or without restricted protection might profit essentially the most.
“You are going to save a fortune and that is additionally so good for general well being care,” Trump mentioned at an occasion Thursday night time unveiling the web site.
The positioning doesn’t promote medicine on to American sufferers, however acts as a central hub that factors them to drugmakers which can be providing reductions on sure merchandise on their very own direct-to-consumer websites, or offers them low cost coupons to take to pharmacies. For instance, Eli Lilly and Novo Nordisk have been already providing their blockbuster weight problems medicine at hefty reductions to cash-paying sufferers, even earlier than the reductions Trump touted on Thursday.
Clicking on the platform’s provide for Lilly’s in style Zepbound weight reduction injection sends shoppers to the corporate’s LillyDirect platform, the place they’ll order the remedy and submit prescription particulars.
A screenshot of a Zepbound order on the TrumpRx web site.
Preview
Filters
Supply Data
In current months, Lilly, Novo and no less than 14 different drugmakers have negotiated agreements with the Trump administration to take part on the platform and voluntarily promote sure medicines at a reduction to Medicaid sufferers. These landmark offers are a part of Trump’s broader “most favored nation” coverage, which pushes to hyperlink U.S. drug costs to the bottom ones overseas.
At launch, the positioning options solely medicines from the primary 5 firms to strike pricing offers with the administration: AstraZeneca, Lilly, EMD Serono, Novo Nordisk and Pfizer, in keeping with a White Home reality sheet. It is going to checklist medicine from different firms “within the coming months,” the administration mentioned.
The platform is the federal government’s newest effort to attempt to rein in U.S. prescription drug costs, that are two to a few occasions larger on common than these in different developed nations — and as much as 10 occasions greater than in sure international locations, in keeping with the Rand Corp., a public coverage suppose tank.
However TrumpRx “does not look like it’s the solely answer” to that situation for many Individuals, mentioned Juliette Cubanski, deputy director of this system on Medicare Coverage at KFF, a well being coverage analysis group. The cash-pay choices could possibly be higher offers for sufferers with out insurance coverage, however it’s tough to evaluate precisely how many individuals stand to learn from TrumpRx, she added.
“In the event that they’re capable of get a drug lined by their insurance coverage at a comparatively reasonably priced copay, then there’s not a terrific upside to utilizing the TrumpRx web site,” Cubanski mentioned.
She mentioned individuals with insurance coverage protection who purchase by way of direct-to-consumer platforms can also not have their purchases depend towards their advantages, which implies it does not assist them meet their deductible or out-of-pocket most.
However Cubanski mentioned there’s potential for TrumpRx to be useful in increasing entry to sure medicine at extra reasonably priced costs, notably medicines not lined extensively by insurance coverage within the U.S., resembling weight problems medicine. Medicare will begin overlaying weight reduction remedies for the primary time later this 12 months as a part of the offers Lilly and Novo struck with Trump, however many employers are nonetheless hesitant to cowl these medicine.
Nonetheless, lots of the different merchandise anticipated to be listed on TrumpRx are already extensively lined by way of insurance coverage, and a few can be found as cheaper generics from competing drugmakers.
Questions on financial savings
Questions stay about how a lot financial savings individuals can count on in the event that they purchase their medicines at direct-to-consumer costs.
The introduced value reductions for sure medicine are framed as steep cuts from their so-called retail checklist costs. For instance, underneath Novo Nordisk’s settlement with the administration, some doses of its diabetes drug Ozempic will probably be priced at $350 monthly on TrumpRx, which is lower than half of its roughly $1,000 month-to-month checklist value.
However these checklist costs are sometimes far larger than what personal insurers and authorities applications finally pay for medicines after rebates, reductions and different concessions, in keeping with researchers at Georgetown’s Medicare Coverage Initiative. That means some payers might already be securing costs similar to — or decrease than — the newly introduced reductions on medicines underneath the Trump offers.
The Georgetown researchers cited one examine that discovered that common reductions on brand-name medicine in Medicare Half D run round 40% of checklist costs. In the meantime, reductions in Medicaid exceed 75%, in accordance to a Congressional Finances Workplace examine.
Within the personal sector, “we have insurers and pharmacy profit managers negotiating decrease costs and designing an insurance coverage profit that allows individuals to learn from these value negotiations,” mentioned KFF’s Cubanski.
“My guess is that for many medicine, no less than most brand-name medicines, persons are prone to get a greater deal utilizing their insurance coverage fairly than buying a drug by way of a direct-to-consumer web site,” she mentioned.
Medicine on TrumpRx
On the launch of the positioning, the administration listed a spread of main medicine as accessible for reductions, with a selected emphasis on in style GLP-1 merchandise:
- Ozempic injection for diabetes, made by Novo Nordisk: Beginning at $199 monthly, down from round $1,000
- Wegovy injection for weight problems, made by Novo Nordisk: Beginning at $199 monthly, down from round $1,350
- Wegovy capsule for weight problems, made by Novo Nordisk: $149 monthly for the beginning doses
- Zepbound injection for weight problems, made by Eli Lilly: beginning at $299 monthly, down from $1,086
The White Home additionally put an emphasis on cash-pay reductions for fertility medicine like Gonal-F from EMD Serono, which was listed at $168.
Dozens of different medicine that firms anticipated to be be listed on the platform weren’t as of Thursday night time. These embody key remedies from firms together with Amgen, Merck and Gilead, amongst others.
In an interview with CNBC at a convention in January, Bristol Myers Squibb CEO Chris Boerner mentioned the corporate has a number of merchandise on its present direct-to-consumer platform, which first supplied a cash-pay low cost on its blood thinner Eliquis. That platform will finally hyperlink to TrumpRx, he mentioned.
The corporate goes to look at methods to place further merchandise in its portfolio by itself platform, “the place it is smart,” Boerner added. He mentioned Bristol Myers is “aligned with the administration” on the difficulty of the U.S. well being care system being too complicated, and mentioned a number of middlemen can improve prices.
“What we like about these [direct-to-consumer models], the place they make sense from a enterprise standpoint, is you are capable of circumvent a few of that,” Boerner mentioned.
In the meantime, in an unique interview with CNBC final week, Eli Lilly CEO Dave Ricks mentioned the corporate was the primary drugmaker to promote weight problems remedies on to sufferers, and that TrumpRx is “taking that and increasing it throughout the business” to different medicines.
“We’re all for that,” Ricks mentioned.
